Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

Investors will be keen to get an update on talc litigation

Healthcare giant Johnson & Johnson (JNJ:NYSE) is expected to report first-quarter earnings on 16 April before the market open. Consensus forecasts call for EPS (earnings per share) of $2.63, a slight fall of 2% compared with the same period in 2023.

Over the prior four quarters the company has bested consensus estimates by an average of around 5% according to Nasdaq.com.

Fourth-quarter 2023 earnings topped expectations helped by strong sales of J&J’s blockbuster psoriasis treatment Stelara, but the drug faces fresh competition this year from biosimilar versions as J&J loses exclusivity.

The company said it expected volumes of surgical procedures to remain above pre-Covid levels during 2024. In February, medical devices maker Becton Dickinson (BDX:NASDAQ) raised its full year earnings guidance after seeing strong demand for surgical equipment.

On 5 April, J&J boosted its medical devices portfolio after agreeing to purchase Shockwave Medical (SWAV:NASDAQ) for about $12.5 billion or $335 per share, representing a 5% premium to the prior closing price.

News of J&J’s interest surfaced on 26 March, sending shares in Shockwave up 11% on the day.

California-based Shockwave makes devices which use shockwaves to break down calcified plaque in heart vessels. 

‹ Previous2024-04-11Next ›